Menu
Back to User profile » Dr James E Foley
Papers published by Dr James E Foley:
DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes
Kozlovski P, Bhosekar V, Foley JE
Vascular Health and Risk Management 2017, 13:123-126
Published Date: 31 March 2017
Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus
Evans M, Schweizer A, Foley JE
Vascular Health and Risk Management 2016, 12:337-340
Published Date: 18 August 2016
Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
Foley JE, Bhosekar V, Kawamori R
Vascular Health and Risk Management 2016, 12:9-12
Published Date: 21 January 2016
Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes
Blüher M, Schweizer A, Bader G, Foley JE
Vascular Health and Risk Management 2014, 10:661-664
Published Date: 20 November 2014
Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin
Schweizer A, Foley JE, Kothny W, Ahrén B
Vascular Health and Risk Management 2013, 9:57-64
Published Date: 15 February 2013
Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W
Vascular Health and Risk Management 2013, 9:21-28
Published Date: 23 January 2013
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
Dejager S, Schweizer A, Foley JE
Vascular Health and Risk Management 2012, 8:339-348
Published Date: 18 May 2012
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
Anja Schweizer, Sylvie Dejager, James E Foley, et al
Vascular Health and Risk Management 2011, 7:49-57
Published Date: 4 February 2011
Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
James E Foley, Jens Jordan
Vascular Health and Risk Management 2010, 6:541-548
Published Date: 1 July 2010